ardelyx inc - ARDX
ARDX
Close Chg Chg %
4.00 0.00 0.00%
Pre-Market
4.00
0.00 (0.00%)
Volume: 10.81M
Last Updated:
Aug 10, 2026, 4:00 PM EDT
Company Overview: ardelyx inc - ARDX
ARDX Key Data
| Open $4.06 | Day Range 3.90 - 4.12 |
| 52 Week Range 3.90 - 8.40 | Market Cap $1.23B |
| Shares Outstanding 247.03M | Public Float 237.16M |
| Beta 0.69 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.24 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.02M |
ARDX Performance
| 1 Week | 0.00% | ||
| 1 Month | -24.24% | ||
| 3 Months | -41.00% | ||
| 1 Year | -23.22% | ||
| 5 Years | 177.78% |
ARDX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About ardelyx inc - ARDX
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
ARDX At a Glance
Ardelyx, Inc.
400 5th Avenue
Waltham, Massachusetts 02451
| Phone | 1-617-675-2739 | Revenue | 407.32M | |
| Industry | Pharmaceuticals: Major | Net Income | -61,599,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 22.093% | |
| Fiscal Year-end | 12 / 2026 | Employees | 489 | |
| View SEC Filings |
ARDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.45 |
| Price to Book Ratio | 8.533 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -35.563 |
| Enterprise Value to Sales | 3.311 |
| Total Debt to Enterprise Value | 0.154 |
ARDX Efficiency
| Revenue/Employee | 832,965.235 |
| Income Per Employee | -125,969.325 |
| Receivables Turnover | 5.669 |
| Total Asset Turnover | 0.868 |
ARDX Liquidity
| Current Ratio | 4.315 |
| Quick Ratio | 4.115 |
| Cash Ratio | 2.987 |
ARDX Profitability
| Gross Margin | 89.542 |
| Operating Margin | -10.06 |
| Pretax Margin | -14.885 |
| Net Margin | -15.123 |
| Return on Assets | -13.126 |
| Return on Equity | -36.209 |
| Return on Total Capital | -16.431 |
| Return on Invested Capital | -17.635 |
ARDX Capital Structure
| Total Debt to Total Equity | 124.561 |
| Total Debt to Total Capital | 55.469 |
| Total Debt to Total Assets | 41.359 |
| Long-Term Debt to Equity | 123.675 |
| Long-Term Debt to Total Capital | 55.074 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ardelyx Inc - ARDX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 52.16M | 124.46M | 333.62M | 407.32M | |
Sales Growth
| +416.57% | +138.61% | +168.06% | +22.09% | |
Cost of Goods Sold (COGS) incl D&A
| 8.72M | 19.09M | 52.62M | 42.60M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.60M | 1.29M | 2.06M | 3.06M | |
Depreciation
| 4.60M | 1.29M | 2.06M | 3.06M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +57.76% | +118.94% | +175.68% | -19.05% | |
Gross Income
| 43.44M | 105.37M | 281.00M | 364.72M | |
Gross Income Growth
| +850.34% | +142.56% | +166.68% | +29.80% | |
Gross Profit Margin
| +83.29% | +84.66% | +84.23% | +89.54% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 107.20M | 168.65M | 308.95M | 405.70M | |
Research & Development
| 34.06M | 34.24M | 50.25M | 68.47M | |
Other SG&A
| 73.14M | 134.40M | 258.69M | 337.23M | |
SGA Growth
| -32.54% | +57.32% | +83.19% | +31.32% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 325.00K | - |
EBIT after Unusual Expense
| (63.76M) | (63.28M) | (28.27M) | (40.98M) | |
Non Operating Income/Expense
| 1.63M | 6.63M | 9.50M | 8.74M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 5.07M | 8.87M | 20.09M | 28.40M | |
Interest Expense Growth
| +12.68% | +74.93% | +126.44% | +41.33% | |
Gross Interest Expense
| 5.07M | 8.87M | 20.09M | 28.40M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (67.20M) | (65.52M) | (38.87M) | (60.63M) | |
Pretax Income Growth
| +57.51% | +2.50% | +40.67% | -55.98% | |
Pretax Margin
| -128.84% | -52.65% | -11.65% | -14.89% | |
Income Tax
| 8.00K | 547.00K | 266.00K | 969.00K | |
Income Tax - Current - Domestic
| 8.00K | 47.00K | 266.00K | 469.00K | |
Income Tax - Current - Foreign
| - | - | 500.00K | 500.00K | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (67.21M) | (66.07M) | (39.14M) | (61.60M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (67.21M) | (66.07M) | (39.14M) | (61.60M) | |
Net Income Growth
| +57.51% | +1.70% | +40.76% | -57.40% | |
Net Margin Growth
| -128.85% | -53.08% | -11.73% | -15.12% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (67.21M) | (66.07M) | (39.14M) | (61.60M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (67.21M) | (66.07M) | (39.14M) | (61.60M) | |
EPS (Basic)
| -0.4235 | -0.3012 | -0.1664 | -0.2556 | |
EPS (Basic) Growth
| +72.10% | +28.88% | +44.75% | -53.61% | |
Basic Shares Outstanding
| 158.69M | 219.33M | 235.23M | 241.03M | |
EPS (Diluted)
| -0.4235 | -0.3012 | -0.1664 | -0.2556 | |
EPS (Diluted) Growth
| +72.10% | +28.88% | +44.75% | -53.61% | |
Diluted Shares Outstanding
| 158.69M | 219.33M | 235.23M | 241.03M | |
EBITDA
| (59.16M) | (61.98M) | (25.89M) | (37.92M) | |
EBITDA Growth
| +60.51% | -4.78% | +58.24% | -46.48% | |
EBITDA Margin
| -113.42% | -49.80% | -7.76% | -9.31% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 16.30 | |
| Number of Ratings | 11 | Current Quarters Estimate | 0.028 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -0.069 | |
| Last Quarter’s Earnings | -0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.26 | Next Fiscal Year Estimate | 0.481 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 10 | 11 | 11 |
| Mean Estimate | 0.03 | 0.10 | -0.07 | 0.48 |
| High Estimates | 0.06 | 0.16 | 0.02 | 0.74 |
| Low Estimate | 0.00 | 0.03 | -0.18 | 0.05 |
| Coefficient of Variance | 75.68 | 43.69 | -98.20 | 44.41 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Ardelyx Inc - ARDX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ardelyx Inc - ARDX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 19, 2026 | William A. Bertrand Director | 329,507 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Muna Bhanji Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Muna Bhanji Director | 163,808 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Robert B. Bazemore Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Robert B. Bazemore Director | 68,006 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Onaiza Cadoret-Manier Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Onaiza Cadoret-Manier Director | 178,156 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | David M. Mott Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | David M. Mott Director | 3,349,655 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | David M. Mott Director | 3,323,200 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Richard J. Rodgers Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | Richard J. Rodgers Director | 439,998 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | William A. Bertrand Director | 39,715 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 19, 2026 | William A. Bertrand Director | 303,052 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2026 | Michael G. Raab President & CEO; Director | 1,877,819 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $0.99 per share | 1,859,040.81 |
| Feb 26, 2026 | Michael G. Raab President & CEO; Director | 1,836,153 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.26 per share | 11,494,317.78 |
| Feb 26, 2026 | Michael G. Raab President & CEO; Director | 395,001 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |